NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-18-036 from the NIH Guide for Grants and Contracts
Notice of Expiration of PAR-16-447 " NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
Notice NOT-AR-18-014 from the NIH Guide for Grants and Contracts
African Association for Health Professions Education and Research (R25)(Clinical Trials Not Allowed)
Funding Opportunity RFA-TW-18-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by supporting the establishment of an African Association for Health Professions Education and Research (the "Association"). The Association will serve as a leadership and convening organization to network institutions across sub-Saharan Africa in order to jointly develop, disseminate, and share best practices, innovations, curricula, and policy and to engage in joint activities that will increase the quantity, quality and retention of African health professionals to address the crisis in HIV/AIDS and its' comorbidities on the continent. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on one or more of the following: Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development, and Outreach to broad communities and multiple stakeholders.
Notice NOT-HL-18-579 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-18-004 from the NIH Guide for Grants and Contracts. The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA's Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generation of devices. In addition, consortia should also provide expertise on evidence generation, including use of real world evidence, for pediatric device development. The pediatric population (i.e., neonates, infants, children, and adolescents) for medical devices is defined as individuals who are younger than 22 years of age (that is, from birth through the twenty-first year of life not including the twenty-second birthday) at the time of diagnosis or treatment.
Notice NOT-GM-18-014 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-034 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-009 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-573 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-574 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-575 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-576 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-577 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-578 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-126 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-572 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-124 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-582 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD. The R21 Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.
Funding Opportunity PAR-18-581 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD. This FOA invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line with the NIH Stage Model.
Funding Opportunity PA-18-566 from the NIH Guide for Grants and Contracts. The overarching goal of the SBIR program at the National Institute of Mental Health (NIMH) is to support small businesses to develop technologies that can advance the mission of the Institute, including in basic neuroscience research relevant to mental disorders, translational and clinical research of mental disorders, clinical diagnosis or treatment of mental disorders, and dissemination of evidence-based mental health care. This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines.